阿布昔替尼片的副作用与注意事项

Abxitinib tablets are developed by Pfizer Pharmaceuticals of the United States. They were approved for marketing in Japan and the European Union in September and December 2021 respectively, for the treatment of moderate to severe atopic dermatitis. Some side effects may occur during use, and special medication precautions need to be understood. This article will introduce in detail the side effects, precautions and efficacy of Abxitinib tablets to help patients better understand this drug.

Side effects of Abxitinib tablets

A variety of side effects may occur during use. Understanding these reactions can help patients identify and take countermeasures in time.

Common side effects

At the 100mg dose, common side effects include nasopharyngitis, nausea, headache, herpes simplex, elevated blood creatine phosphokinase, dizziness, urinary tract infection, etc. These reactions are usually mild and tolerated by most patients.

High dose-related side effects

When the dose is increased to 200 mg, the incidence of side effects may increase, including nausea, headache, herpes simplex, increased blood creatine kinase, dizziness, urinary tract infection, acne, vomiting, etc. Some patients may experience epigastric pain, abdominal discomfort, herpes zoster, and thrombocytopenia.

Serious adverse reactions

Abxitinib tablets may cause severe infections, malignant tumors, thrombosis and other serious adverse reactions. An increased risk of infections such as herpes zoster and pneumonia, as well as cases of deep vein thrombosis and pulmonary embolism, have been observed in clinical studies.

The side effects of Abxitinib tablets vary depending on the dose and individual differences. Patients should closely observe their body reactions during medication and communicate with their doctors in a timely manner.

Precautions for Absitinib Tablets

Patients should pay special attention to the following matters when using Absitinib Tablets.

Risk of infection

Abxitinib tablets may increase the risk of infection and should be avoided in patients with active severe infections. The risk of tuberculosis needs to be assessed before taking medication, and preventive treatment should be carried out if necessary. Signs of infection should be monitored during treatment, and treatment must be discontinued immediately if serious infection occurs.

Cardiovascular and thrombotic risks

This drug may increase the risk of major cardiovascular adverse events and thrombosis. Patients with a history of cardiovascular disease or thrombosis risk should use the drug with caution and seek medical attention promptly when relevant symptoms occur.

Usage in Special Populations

Pregnant women, lactating women, children and patients with severe liver and kidney damage should avoid using Abxitinib tablets. Elderly patients need to closely monitor their platelet count and risk of infection when taking the drug.

The precautions for Abxitinib Tablets involve many aspects such as infection, cardiovascular risk, and medication for special groups. Patients must strictly follow the doctor's instructions.

Efficacy of Absitinib Tablets

Absitinib Tablets have shown significant efficacy in the treatment of chronic kidney disease related to type 2 diabetes.

Main therapeutic effects

The drug can effectively reduce the risk of sustained decline in estimated glomerular filtration rate, reduce the incidence of end-stage renal disease, cardiovascular death and hospitalization for heart failure.

Relationship between dose and efficacy

The conventional recommended dose is 100 mg once a day. If the efficacy is insufficient, it can be increased to 200 mg once a day. Some patients may need to adjust to a maintenance dose after initial high-dose treatment for 12 weeks.

Long-term treatment effect

Clinical studies have shown that long-term treatment with Abxitinib tablets can significantly improve patient prognosis. If there is no obvious effect after 12 weeks of medication, discontinuation of the medication should be considered; some patients may achieve further improvement by continuing treatment.

The efficacy of Abxitinib tablets has been verified in multiple clinical studies, providing patients with an important treatment option.